Theodore M Kamenecka

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3868952/publications.pdf

Version: 2024-02-01

79 papers	4,781 citations	147801 31 h-index	98798 67 g-index
87 all docs	87 docs citations	87 times ranked	6605 citing authors

#	Article	IF	Citations
1	Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature, 2012, 485, 62-68.	27.8	638
2	Antidiabetic actions of a non-agonist PPARÎ³ ligand blocking Cdk5-mediated phosphorylation. Nature, 2011, 477, 477-481.	27.8	484
3	Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand. Nature, 2011, 472, 491-494.	27.8	446
4	Partial Agonists Activate PPARÎ³ Using a Helix 12 Independent Mechanism. Structure, 2007, 15, 1258-1271.	3.3	321
5	The Secreted Enzyme PM20D1 Regulates Lipidated Amino Acid Uncouplers of Mitochondria. Cell, 2016, 166, 424-435.	28.9	188
6	Selective Chemical Inhibition of PGC-1Î± Gluconeogenic Activity Ameliorates Type 2 Diabetes. Cell, 2017, 169, 148-160.e15.	28.9	153
7	Identification of SR8278, a Synthetic Antagonist of the Nuclear Heme Receptor REV-ERB. ACS Chemical Biology, 2011, 6, 131-134.	3.4	152
8	An alternate binding site for PPARÎ³ ligands. Nature Communications, 2014, 5, 3571.	12.8	148
9	Ligand and Receptor Dynamics Contribute to the Mechanism of Graded PPARÎ³ Agonism. Structure, 2012, 20, 139-150.	3.3	133
10	Identification of SR2211: A Potent Synthetic RORÎ³-Selective Modulator. ACS Chemical Biology, 2012, 7, 672-677.	3.4	126
11	Regulation of Adipogenesis by Natural and Synthetic REV-ERB Ligands. Endocrinology, 2010, 151, 3015-3025.	2.8	115
12	Pharmacological repression of PPARÎ³ promotes osteogenesis. Nature Communications, 2015, 6, 7443.	12.8	99
13	Pharmacological targeting of the mammalian clock regulates sleep architecture and emotional behaviour. Nature Communications, 2014, 5, 5759.	12.8	98
14	Pharmacologic Repression of Retinoic Acid Receptorâ€“Related Orphan Nuclear Receptor Î³ Is Therapeutic in the Collagenâ€Induced Arthritis Experimental Model. Arthritis and Rheumatology, 2014, 66, 579-588.	5.6	81
15	Habenular TCF7L2 links nicotine addiction to diabetes. Nature, 2019, 574, 372-377.	27.8	81
16	REV-ERBÎ± Regulates TH17 Cell Development and Autoimmunity. Cell Reports, 2018, 25, 3733-3749.e8.	6.4	78
17	Suppression of atherosclerosis by synthetic REV-ERB agonist. Biochemical and Biophysical Research Communications, 2015, 460, 566-571.	2.1	73
18	ROR Inverse Agonist Suppresses Insulitis and Prevents Hyperglycemia in a Mouse Model of Type 1 Diabetes. Endocrinology, 2015, 156, 869-881.	2.8	60

#	Article	IF	Citations
19	The nuclear receptor REV-ERBÎ± modulates Th17 cell-mediated autoimmune disease. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 18528-18536.	7.1	60
20	Siteâ€Selective Î³â€C(sp³)â^'H and Î³â€C(sp²)â^'H Arylation of Free Amino Esters Promoted by a Catalytic Transient Directing Group. Chemistry - A European Journal, 2018, 24, 9535-9541.	3.3	54
21	Defining a conformational ensemble that directs activation of PPARÎ³. Nature Communications, 2018, 9, 1794.	12.8	53
22	Native Directed Site-Selective Î´-C(sp³)â€“H and Î´-C(sp²)â€“H Arylation of Primary Amines. ACS Catalysis, 2019, 9, 4887-4891.	11.2	49
23	Synthetic RORÎ³t Agonists Enhance Protective Immunity. ACS Chemical Biology, 2016, 11, 1012-1018.	3.4	48
24	Dipyridyl amides: potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 1197-1200.	2.2	46
25	PPARÎ³ in Complex with an Antagonist and Inverse Agonist: a Tumble and Trap Mechanism of the Activation Helix. IScience, 2018, 5, 69-79.	4.1	40
26	An Accessory Agonist Binding Site Promotes Activation of Î±4Î²2* Nicotinic Acetylcholine Receptors. Journal of Biological Chemistry, 2015, 290, 13907-13918.	3.4	38
27	A structural mechanism for directing corepressor-selective inverse agonism of PPARÎ³. Nature Communications, 2018, 9, 4687.	12.8	38
28	Modification of the Orthosteric PPARÎ³ Covalent Antagonist Scaffold Yields an Improved Dual-Site Allosteric Inhibitor. ACS Chemical Biology, 2017, 12, 969-978.	3.4	36
29	Inhibitors of c-jun-N-Terminal Kinase (JNK). Mini-Reviews in Medicinal Chemistry, 2008, 8, 755-766.	2.4	35
30	3,5-Disubstituted quinolines as novel c-Jun N-terminal kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 6378-6382.	2.2	34
31	Assessment of NR4A Ligands That Directly Bind and Modulate the Orphan Nuclear Receptor Nurr1. Journal of Medicinal Chemistry, 2020, 63, 15639-15654.	6.4	34
32	Antiobesity Effect of a Small Molecule Repressor of RORÎ³. Molecular Pharmacology, 2015, 88, 48-56.	2.3	33
33	Complexes of the neurotensin receptor 1 with small-molecule ligands reveal structural determinants of full, partial, and inverse agonism. Science Advances, 2021, 7, .	10.3	32
34	Development of novel NEMO-binding domain mimetics for inhibiting IKK/NF-ÎºB activation. PLoS Biology, 2018, 16, e2004663.	5.6	29
35	Small molecule amides as potent ROR-Î³ selective modulators. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 532-536.	2.2	28
36	Synthesis of 2-aryl-2H-tetrazoles via a regioselective [3+2] cycloaddition reaction. Tetrahedron Letters, 2016, 57, 1597-1599.	1.4	27

#	Article	IF	Citations
37	Genetic and pharmacological inhibition of the nuclear receptor RORÎ± regulates TH17 driven inflammatory disorders. Nature Communications, 2021, 12, 76.	12.8	27
38	Synthesis and SAR of piperazine amides as novel c-jun N-terminal kinase (JNK) inhibitors. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 3344-3347.	2.2	25
39	Synthesis and SAR of novel isoxazoles as potent c-jun N-terminal kinase (JNK) inhibitors. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 161-164.	2.2	24
40	N-Arylsulfonyl Indolines as Retinoic Acid Receptor-Related Orphan Receptorâ€…Î³ (RORÎ³) Agonists. ChemMedChem, 2016, 11, 2607-2620.	3.2	24
41	Probing the Complex Binding Modes of the PPARÎ³ Partial Agonist 2-Chloro-N-(3-chloro-4-((5-chlorobenzo[d]thiazol-2-yl)thio)phenyl)-4-(trifluoromethyl)benzenesulfonamide (T2384) to Orthosteric and Allosteric Sites with NMR Spectroscopy. Journal of Medicinal Chemistry, 2016, 59, 10335-10341.	6.4	24
42	Unorthodox Acetylcholine Binding Sites Formed by Î±5 and Î²3 Accessory Subunits in Î±4Î²2* Nicotinic Acetylcholine Receptors. Journal of Biological Chemistry, 2016, 291, 23452-23463.	3.4	24
43	Chemical Crosslinking Mass Spectrometry Reveals the Conformational Landscape of the Activation Helix of PPARÎ³; a Model for Ligand-Dependent Antagonism. Structure, 2018, 26, 1431-1439.e6.	3.3	24
44	Novel small molecule inhibition of IKK/NFâ€ºB activation reduces markers of senescence and improves healthspan in mouse models of aging. Aging Cell, 2021, 20, e13486.	6.7	24
45	Synthesis and SAR of tetrahydroisoquinolines as Rev-erbÎ± agonists. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 3739-3742.	2.2	22
46	Structureâ€“Activity Relationship of 2,4-Dichloro-N-(3,5-dichloro-4-(quinolin-3-yloxy)phenyl)benzenesulfonamide (INT131) Analogs for PPARÎ³-Targeted Antidiabetics. Journal of Medicinal Chemistry, 2017, 60, 4584-4593.	6.4	22
47	Quantitative structural assessment of graded receptor agonism. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 22179-22188.	7.1	21
48	Discovery of Hydrolysis-Resistant Isoindoline N-Acyl Amino Acid Analogues that Stimulate Mitochondrial Respiration. Journal of Medicinal Chemistry, 2018, 61, 3224-3230.	6.4	20
49	Definition of functionally and structurally distinct repressive states in the nuclear receptor PPARÎ³. Nature Communications, 2019, 10, 5825.	12.8	20
50	Neuron-based high-content assay and screen for CNS active mitotherapeutics. Science Advances, 2020, 6, eaaw8702.	10.3	20
51	Pharmacological modulation and genetic deletion of REV-ERBÎ± and REV-ERBÎ² regulates dendritic cell development. Biochemical and Biophysical Research Communications, 2020, 527, 1000-1007.	2.1	20
52	Synthesis and SAR of 4-(pyrazol-3-yl)-pyridines as novel c-jun N-terminal kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 2732-2735.	2.2	18
53	Synthesis and activity of substituted heteroaromatics as positive allosteric modulators for Î±4Î²2Î±5 nicotinic acetylcholine receptors. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 674-678.	2.2	18
54	RORÎ± modulates semaphorin 3E transcription and neurovascular interaction in pathological retinal angiogenesis. FASEB Journal, 2017, 31, 4492-4502.	0.5	18

#	Article	IF	Citations
55	Synthesis and SAR of 2-Phenoxypyridines as novel c-Jun N-terminal kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 7072-7075.	2.2	16
56	Small molecule tertiary amines as agonists of the nuclear hormone receptor Rev-erbÎ±. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 4413-4417.	2.2	16
57	Amidines as amide bond replacements in VLA-4 antagonists. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 2323-2326.	2.2	14
58	N-Aryl-prolyl-dipeptides as potent antagonists of VLA-4. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 2205-2208.	2.2	13
59	HDX-MS reveals structural determinants for RORÎ³ hyperactivation by synthetic agonists. ELife, 2019, 8, .	6.0	12
60	REV-ERBÎ± regulates age-related and oxidative stress-induced degeneration in retinal pigment epithelium via NRF2. Redox Biology, 2022, 51, 102261.	9.0	12
61	Chemical systems biology reveals mechanisms of glucocorticoid receptor signaling. Nature Chemical Biology, 2021, 17, 307-316.	8.0	11
62	Dipyridyl amines: Potent metabotropic glutamate subtype 5 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 4350-4353.	2.2	10
63	Synthesis of novel steroidal agonists, partial agonists, and antagonists for the glucocorticoid receptor. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 347-353.	2.2	10
64	Design, synthesis, and evaluation of simple phenol amides as ERRÎ³ agonists. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 1313-1319.	2.2	9
65	Identification of an aminothiazole series of RORÎ² modulators. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 1178-1181.	2.2	8
66	Discovery of an intrasubunit nicotinic acetylcholine receptorâ€“binding site for the positive allosteric modulator Br-PBTC. Journal of Biological Chemistry, 2019, 294, 12132-12145.	3.4	8
67	Unique Polypharmacology Nuclear Receptor Modulator Blocks Inflammatory Signaling Pathways. ACS Chemical Biology, 2019, 14, 1051-1062.	3.4	8
68	Design and synthesis of 1-aryl-5-anilinoindazoles as c-Jun N-terminal kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 2683-2687.	2.2	7
69	The discovery of indole full agonists of the neurotensin receptor 1 (NTSR1). Bioorganic and Medicinal Chemistry Letters, 2014, 24, 3974-3978.	2.2	7
70	Promoting activity of (Î±4)3(Î²2)2 nicotinic cholinergic receptors reduces ethanol consumption. Neuropsychopharmacology, 2020, 45, 301-308.	5.4	7
71	Structural and Dynamic Elucidation of a Non-acid PPARÎ³ Partial Agonist: SR1988. Nuclear Receptor Research, 2018, 5, .	2.5	5
72	Conformational Changes of RORÎ³ During Response Element Recognition and Coregulator Engagement. Journal of Molecular Biology, 2021, 433, 167258.	4.2	4

#	Article	IF	Citations
73	A simple and robust cell-based assay for the discovery of novel cytokinesis inhibitors. Journal of Biological Methods, 2020, 7, e136.	0.6	4
74	Identification of potent RORÎ² modulators: Scaffold variation. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 3210-3215.	2.2	3
75	High throughput screening for compounds to the orphan nuclear receptor NR2F6. SLAS Discovery, 2022, 27, 242-248.	2.7	3
76	Structureâ€“Activity Relationship and Biological Investigation of SR18292 (16), a Suppressor of Glucagon-Induced Glucose Production. Journal of Medicinal Chemistry, 2021, 64, 980-990.	6.4	2
77	Discovery of Selective Inhibitors for In Vitro and In Vivo Interrogation of Skeletal Myosin II. ACS Chemical Biology, 2021, 16, 2164-2173.	3.4	2
78	Discovery and Optimization of a Series of Sulfonamide Inverse Agonists for the Retinoic Acid Receptor-Related Orphan Receptor-Î±. Medicinal Chemistry, 2019, 15, 676-684.	1.5	2
79	Synthesis and structure activity relationship of the first class of LXR inverse agonists. Bioorganic Chemistry, 2022, 119, 105540.	4.1	2